"10.1371_journal.pone.0080330","plos one","2013-11-12T00:00:00Z","Anna Lindgren; Malin Levin; Sandra Rodrigo Blomqvist; Johannes Wikström; Andrea Ahnmark; Christina Mogensen; Gerhard Böttcher; Mohammad Bohlooly-Y; Jan Borén; Li-Ming Gan; Daniel Lindén","Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden; Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Discovery Sciences, Transgenics, AstraZeneca R&D, Mölndal, Sweden; Global Safety Assessment, Pathology Sciences, AstraZeneca R&D, Mölndal, Sweden","Conceived and designed the experiments: AL ML MB-Y JB L-MG DL. Performed the experiments: AL ML SRB JW AA CM DL. Analyzed the data: AL ML SRB JW GB DL. Wrote the manuscript: AL ML DL.","AL, SRB, JW, AA, CM, GB, MB-Y, L-MG and DL are employes of AstraZeneca, the funder of this study. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Anna Lindgren","AL",11,TRUE,6,7,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
